Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes, has started phase III trials. If it reaches the market, the oral formulation ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

In this edition of Deep Dive, delve into the revolutionary world of genetic editing as we trace the development of CRISPR, discover why Alexion’s Soraya Bekkali believes now it the time to ...